Awakn Life Sciences Corp
Awakn Life Sciences Corp., a biotechnology company, engages in the research, development, operation, and delivery of psychedelic therapeutics to treat addiction and other mental health conditions in North America and Europe. It develops AWKN-001, a novel medication-assisted treatments (MAT) consisting of racemic ketamine, delivered intravenously, and manualized relapse prevention cognitive behavi… Read more
Awakn Life Sciences Corp (AWKNF) - Total Liabilities
Latest total liabilities as of October 2024: $2.19 Million USD
Based on the latest financial reports, Awakn Life Sciences Corp (AWKNF) has total liabilities worth $2.19 Million USD as of October 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Awakn Life Sciences Corp - Total Liabilities Trend (2021–2024)
This chart illustrates how Awakn Life Sciences Corp's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Awakn Life Sciences Corp Competitors by Total Liabilities
The table below lists competitors of Awakn Life Sciences Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Bounty Oil & Gas NL
PINK:BYOGF
|
USA | $4.08 Million |
|
Scinai Immunotherapeutics Ltd
NASDAQ:SCNI
|
USA | $3.98 Million |
|
THALES - Dusseldorf Stock Exchang
DU:CSF
|
Germany | €31.82 Billion |
|
Simble Solutions Ltd
AU:SIS
|
Australia | AU$1.22 Million |
|
Sadot Group Inc.
NASDAQ:SDOT
|
USA | $49.28 Million |
|
Tianrong Internet Products and Services Inc
PINK:TIPS
|
USA | $1.26 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Awakn Life Sciences Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.44 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 3.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Awakn Life Sciences Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Awakn Life Sciences Corp (2021–2024)
The table below shows the annual total liabilities of Awakn Life Sciences Corp from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-01-31 | $2.07 Million | -53.33% |
| 2023-01-31 | $4.44 Million | +15.31% |
| 2022-01-31 | $3.85 Million | +969.04% |
| 2021-01-31 | $360.45K | -- |